Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results
Objectives Recently, the results of two economic evaluations were published both of which seemingly demonstrate the cost-effectiveness of sofosbuvir-based regimens for the treatment of chronic hepatitis C genotype 1 infection in Germany. Both analyses were sponsored by the manufacturer of sofosbuvir...
Main Authors: | Afschin Gandjour, George Vousden |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531817/?tool=EBI |
Similar Items
-
Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
by: Afschin Gandjour
Published: (2020-01-01) -
Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".
by: Axel C Mühlbacher, et al.
Published: (2021-01-01) -
Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
by: Jona T Stahmeyer, et al.
Published: (2017-01-01) -
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
by: Phil McEwan, et al.
Published: (2017-07-01) -
Daclatasvir/Sofosbuvir versus Ledipasvir/Sofosbuvir in Patients with Hepatitis C Virus Infection Genotypes 1 and 3
by: Narjes Shokatpour, et al.
Published: (2020-06-01)